Adalimumab in ulcerative colitis: hypes and hopes

Bibliography

• Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Tumour necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006;12:4807-12
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO, Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17
   PubMed Web of Science ®Google Scholar
• Murch SH, Braegger CP, Walker-Smith JA, MacDonald. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34;1705-9
   PubMed Web of Science ®Google Scholar
• Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis 2008;40(Suppl 2):S225-8
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan B, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;233:2462-73
   Google Scholar
• Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;341:601-8
   Google Scholar
• Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000;355(9205):735-40
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. J Crohn's Colitis 2010;4(1):S5
   Google Scholar
• Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13:2328-32
   PubMed Web of Science ®Google Scholar
• Oussalah A, Laclotte C, Chevaux JB, Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-72
   PubMed Web of Science ®Google Scholar
• Afif W, Leighton JA, Hanauer SB, Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-7
   PubMed Web of Science ®Google Scholar
• Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010;32:522-8
   PubMed Web of Science ®Google Scholar
• Taxonera C, Estelles J, Blanco I, Adalimumab for ulcerative colitis patients previously treated with infliximab: outcomes at short and long term and predictors of response. Gastroenterology 2010;138(5):S61
   Google Scholar
• Hudis N, Rajca B, Polyak S, The outcome of active ulcerative colitis treated with adalimumab. Gastroenterology 2009;136(5):A661
   Web of Science ®Google Scholar
• Garcia-Bosch O, Aceituno M, Perez J, Efficacy of adalimumab in the treatment of ulcerative colitis. J Crohn's Colitis 2010;4(1):S55
   Google Scholar
• Barreiro-de Acosta M, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009;15:3814-16
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Feagan BG, Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11
   PubMed Web of Science ®Google Scholar
• D'Haens G, Baert F, van Assche G, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371(9613):660-7
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
   PubMed Web of Science ®Google Scholar
• Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807AM3). Bethesda, MD: clinicaltrials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00537316?term=NCT00537316.&rank=1 [Last accessed 20 November 2010]
   Google Scholar